CorMedix Reports Second Quarter 2013 Results

Published: Aug 15, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BRIDGEWATER, N.J., Aug. 14, 2013 /PRNewswire/ -- CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announces its financial results for the second quarter ended June 30, 2013. With the receipt in July 2013 of the CE Mark for Neutrolin®, CorMedix is now focused on commercializing Neutrolin in the European Union and rest of world. CorMedix estimates the market potential for Neutrolin to be between $300 - 400 million.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news